Therapy: Immunogenicity of biologic therapies-we need tolerance.
Krieckaert
Charlotte L M
CL
Bartelds
G Margret
GM
Wolbink
Gerrit-Jan
GJ
D000074323:Alemtuzumab; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000276:immunology* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000276:immunology* / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D004306:Dose-Response Relationship, Immunologic; D004334:Drug Administration Schedule; D006801:Humans; D007108:Immune Tolerance; D007167:Immunotherapy; D051379:Mice; D011485:Protein Binding / Q000276:immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab